Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Phosphatidylinositol 3-Kinase (PI3K) family is a group of intracellular enzymes that phosphorylate phosphoinositides, playing crucial roles in cell growth, proliferation, survival, and metabolism. They are divided into three classes (I, II, and III) based on structure and substrate specificity. Dysregulation of PI3K signaling is frequently observed in cancer, making it an attractive therapeutic target. Class I PI3Ks are the most studied due to their central role in cancer biology and immune regulation. Several small molecule inhibitors targeting specific isoforms have been developed.
Inhibition of PI3K enzymatic activity, blocking downstream signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 3-Kinase Family (PI3K).